Drug intelligence / Profile preview

rocuronium + sugammadex

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules, Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Rocuronium + sugammadex is a combination used in anesthesia practice. Rocuronium is a non-depolarizing neuromuscular blocking agent (muscle relaxant) that induces temporary paralysis by competitively inhibiting acetylcholine at the neuromuscular junction, facilitating endotracheal intubation and providing skeletal muscle relaxation during surgery or mechanical ventilation. Sugammadex is a modified gamma-cyclodextrin that acts as a selective relaxant binding agent; it rapidly reverses the effects of steroidal non-depolarizing neuromuscular blockers like rocuronium by encapsulating and inactivating them, thereby restoring normal muscle function. This combination allows for rapid onset of paralysis with controlled and predictable reversal, improving safety and efficiency in surgical procedures[1][2][3][5][6].

Brand names
BridionEsmeron + BridionSugagelan
Other names
Moderate Neuromuscular Blockade GroupControl Group (Yonsei University Thyroidectomy Study)
02

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on rocuronium + sugammadex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rocuronium + sugammadex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call